poliovirus type 2 mef-1 strain inactivated
PolandDrugs containing this active substance
-
This is a vaccine used as a booster dose in children over 6 years of age, adolescents, and adults. It is used for the simultaneous prevention of diphtheria, tetanus, and poliomyelitis.
Form: suspension for injection
Active substance Dosage poliovirus type 1 mahoney strain inactivated 1,245 g/10 ml diphtheria toxoid 0.01 g/10 ml poliovirus type 2 mef-1 strain inactivated ad 1 ml tetanus toxoid 0.01 g/10 ml poliovirus type 3 sabin strain inactivated 32 units of antigen D ATC: J07CA01
Manufacturer: Sanofi Pasteur Sanofi-Aventis Ltd.
-
The vaccine is used to prevent poliomyelitis (polio) in infants, children, adolescents, and adults. It may be used as part of a primary vaccination schedule or as a booster dose.
Form: solution for injection in ampoule-syringe
Active substance Dosage poliovirus type 1 mahoney strain inactivated 29 units of antigen D inactivated poliomyelitis vaccine 0.5 ml poliovirus type 2 mef-1 strain inactivated 7 units of antigen D poliovirus type 3 sabin strain inactivated 26 units of antigen D ATC: J07BF03
Manufacturer: Sanofi Winthrop Industry Sanofi Winthrop Industry Sanofi-Aventis Ltd.
-
The vaccine helps protect the child against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio).
Form: solution for injection in ampoule-syringe
Active substance Dosage diphtheria toxoid minimum 30 IU tetanus toxoid minimum 40 IU bordetella pertussis antigens 25 micrograms poliovirus type 1 mahoney strain inactivated 40 units of antigen D poliovirus type 2 mef-1 strain inactivated 8 units of antigen D poliovirus type 3 sabin strain inactivated 32 units of antigen D ATC: J07CA02
Manufacturer: Sanofi Winthrop Industry Sanofi Winthrop Industry Sanofi-Aventis Ltd.